Table 4.

Ongoing phase II clinical trial combining mTOR inhibitors with fulvestrant

Study name (ClinicalTrials.gov identifier)	Study arms	Study population	Outcome measures
NCT02049957	MLN0128(Dual mTORC1/2 Inhibitor) + Fulvestrant	Postmenopausal women with HR+/HER2− advanced or metastatic BC that has progressed on treatment with everolimus in combination with exemestane or fulvestrant	Percentage of patients experiencing AEs, CBR, ORR, and PFS

AE, adverse event; BC, breast cancer; CBR, clinical benefit rate; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; ORR, overall response rate; PFS, progression‐free survival.